Partial
Partially Aligned
Patient Risk:
Medium
Summary
Most liver-related safety statements align with label guidance on liver enzyme abnormalities, monitoring, caution, and management (dose reduction/withdrawal). However, several claims are not supported or are overstated relative to the provided label excerpts—specifically hepatitis linkage, explicit hepatitis/cirrhosis/liver cancer contraindication details, and characterization of hepatic failure as 'rare' and 'particularly' increased risk.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can cause liver enzyme elevations.
Supported by 5.2 Liver Dysfunction (biochemical abnormalities; persistent elevations in serum transaminases).
Individuals with pre-existing liver conditions should be closely monitored for liver enzyme elevations and other signs of liver damage.
Supported by 5.2 Liver Dysfunction (monitor patients with increased transaminase levels; caution in patients with history of liver disease).
Regular LFTs should be performed to monitor liver function and detect potential liver damage in individuals with pre-existing liver conditions.
Supported by 5.2 Liver Dysfunction and 17.2 Liver Enzymes (perform LFTs prior to and at 12 weeks after initiation/after dose increases; periodically thereafter).
The dose of Lipitor may need to be adjusted based on liver function and the presence of pre-existing liver conditions.
Supported by 5.2 Liver Dysfunction (recommend reduction of dose or withdrawal if ALT/AST >3 times ULN persist; upon dose reduction/transaminases returned near pretreatment levels).
Unsupported Statements
Lipitor has been linked to cases of hepatitis.
The provided label excerpts do not mention hepatitis.
Alternative treatments may be necessary for individuals with pre-existing liver conditions.
The provided label excerpts recommend caution and dose reduction/withdrawal based on persistent enzyme elevations, but do not explicitly state that alternative treatments are necessary.
Contradictions
Important Omissions
No explicit labeling language about the recommended threshold/management wording for persistent ALT/AST elevations being a basis for dose reduction/withdrawal (rather than framing it as a contraindication for elevated LFTs).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some claims are overstated relative to the provided label excerpts (hepatitis linkage; specificity of contraindications including hepatitis/cirrhosis/liver cancer; and characterization of hepatic failure as 'rare' and liver damage risk 'particularly' increased). While monitoring and dose-management concepts broadly align, the overstated or unsupported specifics could misinform risk interpretation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Unlabelled/overstated specifics: hepatitis linkage, specific contraindication details (hepatitis/cirrhosis/liver cancer), and 'rare' characterization of hepatic failure and 'particularly' increased risk framing.
Suggested Improvement
Rephrase to match label language in the provided excerpts: describe 'active liver disease' contraindication without adding unsupported specific conditions (hepatitis/cirrhosis/liver cancer), avoid stating 'rare' hepatic failure, and replace 'hepatitis' with label-supported transaminase elevations and the monitoring/dose-reduction/withdrawal approach (ALT/AST >3× ULN persist).